PGEN Precigen Inc
Price (delayed)
$0.9729
Market cap
$245.91M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.54
Enterprise value
$242.91M
Precigen is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases
Highlights
Precigen's debt has decreased by 20% YoY and by 5% from the previous quarter
PGEN's gross profit has dropped by 161% since the previous quarter and by 104% year-on-year
PGEN's gross margin has plunged by 119% YoY
Key stats
What are the main financial stats of PGEN
Market
Valuations
Earnings
Shares outstanding
252.76M
Market cap
$245.91M
Enterprise value
$242.91M
Price to earnings (P/E)
N/A
Price to book (P/B)
5.69
Price to sales (P/S)
55.94
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
55.34
Revenue
$4.39M
EBIT
-$137.43M
EBITDA
-$130.97M
Free cash flow
-$77.89M
Per share
Balance sheet
Liquidity
EPS
-$0.54
Free cash flow per share
-$0.31
Book value per share
$0.17
Revenue per share
$0.02
TBVPS
$0.17
Total assets
$73.16M
Total liabilities
$29.99M
Debt
$6.34M
Equity
$43.17M
Working capital
$692,000
Debt to equity
0.15
Current ratio
1.03
Quick ratio
0.89
Net debt/EBITDA
0.02
Margins
Efficiency
Dividend
EBITDA margin
-2,984.1%
Gross margin
-13.6%
Net margin
-3,084.6%
Operating margin
-3,199.2%
Return on assets
-98.5%
Return on equity
-133.3%
Return on invested capital
-296.8%
Return on capital employed
-274.1%
Return on sales
-3,131.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PGEN stock price
How has the Precigen stock price performed over time
Intraday
-0.6%
1 week
0.82%
1 month
-11.55%
1 year
-38.81%
YTD
-27.4%
QTD
-38.42%
Financial performance
How have Precigen's revenue and profit performed over time
Revenue
$4.39M
Gross profit
-$595,000
Operating income
-$140.41M
Net income
-$135.38M
Gross margin
-13.6%
Net margin
-3,084.6%
PGEN's gross profit has dropped by 161% since the previous quarter and by 104% year-on-year
PGEN's gross margin has plunged by 119% YoY
Precigen's operating income has plunged by 90% YoY and by 39% from the previous quarter
Precigen's revenue has plunged by 80% YoY and by 19% from the previous quarter
Growth
What is Precigen's growth rate over time
Valuation
What is Precigen stock price valuation
P/E
N/A
P/B
5.69
P/S
55.94
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
55.34
Precigen's EPS has decreased by 38% QoQ
PGEN's equity has dropped by 74% year-on-year and by 56% since the previous quarter
PGEN's P/B is 24% above its last 4 quarters average of 4.6 but 23% below its 5-year quarterly average of 7.4
PGEN's P/S is 96% below its 5-year quarterly average of 1248.4 and 15% below its last 4 quarters average of 65.5
Precigen's revenue has plunged by 80% YoY and by 19% from the previous quarter
Efficiency
How efficient is Precigen business performance
The ROIC has plunged by 96% from the previous quarter
PGEN's return on equity has dropped by 82% since the previous quarter
Precigen's return on sales has shrunk by 75% QoQ
The ROA has plunged by 74% from the previous quarter
Dividends
What is PGEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PGEN.
Financial health
How did Precigen financials performed over time
The company's total assets is 144% higher than its total liabilities
PGEN's quick ratio has plunged by 73% YoY and by 44% from the previous quarter
PGEN's current ratio has dropped by 70% year-on-year and by 40% since the previous quarter
Precigen's debt is 85% less than its equity
PGEN's debt to equity has soared by 200% YoY and by 114% from the previous quarter
PGEN's equity has dropped by 74% year-on-year and by 56% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.